Sequana Medical announces results of the MOSAIC trial data presented at 2017 AASLD

Zurich, Switzerland: 24 October 2017 - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, presented the findings of the MOSAIC study data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), held in Washington, DC.

This North American prospective, open label, single arm, multi-centre study comprised 30 cirrhotic patients with recurrent large ascites, and not eligible for TIPS. Lead investigators of the study, Professor Florence Wong from University of Toronto, Toronto, ON, Canada and Professor Patrick Kamath from Mayo Clinic College of Medicine and Science, Rochester, MN concluded: "alfapump implantation resulted in a clinically significant improvement in mean quality of life, as measured by CLDQ and AscitesQ (two validated questionnaires), and elimination of LVP requirement in 70% of patients at 3 months. Study patients had greater than expected overall survival compared with prior publications. Reinterventions, explants and adverse events related to AKI and infection remain as concerns. Further studies should include revised catheter design and procedural and post-procedure care algorithms."

More info on Sequana's website.


Next > Nexstim raises € 1.75 million via a directed issue of new shares to London-based investor City Financial - Funds to be used to support beginning the commercialisation of its NBT® system

Previous > Emmanuel Blin named Chairman of the Board at Noona Healthcare